Cryoport, Inc. (CYRX) Earnings
Cryoport, Inc. is expected to report next earnings on August 4, 2026 (in NaN days), with a consensus EPS estimate of $-0.20. CYRX has beaten EPS estimates in 3 of its last 12 reported quarters (average surprise -12.1% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 4, 2026 | $-0.20 | $-0.23 | -15.0% | $48M | +6.5% |
| Mar 3, 2026 | $-0.19 | $-0.21 | -10.5% | $45M | +1.8% |
| May 7, 2025 | $-0.23 | $-0.22 | +4.3% | $41M | -3.3% |
| Mar 4, 2025 | $-0.33 | $-0.42 | -27.3% | $60M | +1.2% |
| Nov 7, 2024 | $-0.29 | $-0.02 | +93.1% | $57M | -3.6% |
| Mar 12, 2024 | $-0.32 | $-0.51 | -59.4% | $57M | -2.0% |
| May 4, 2023 | $-0.19 | $-0.16 | +15.8% | $63M | +1.1% |
| Feb 23, 2023 | $-0.19 | $-0.24 | -26.3% | $60M | +3.6% |
| Nov 3, 2022 | $-0.14 | $-0.15 | -7.1% | $60M | -13.6% |
| Aug 4, 2022 | $-0.15 | $-0.17 | -13.3% | $64M | -0.7% |
| May 5, 2022 | $-0.20 | $-0.31 | -55.0% | $52M | +0.1% |
| Feb 24, 2022 | $-0.15 | $-1.32 | -780.0% | $56M | -2.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 4, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- First quarter results show market leading position with 16% revenue growth year over year. - Revenue in support of commercial cell and gene therapy grew 26% and clinical trials grew 18%. - Supported a record 766 global clinical trials as of March 31st. - Rocket Pharmaceutical's gene therapy received accelerated approval, increasing commercial therapies supported to 21. - Life sciences services segment had 18% revenue growth, including 21% growth in bio storage services. - Life Sciences product segment had 15% revenue growth driven by MVE Biological Solutions cryogenic systems. - IntegraCell team shipped first cryopreserved clinical trial patient materials from Houston, Texas, and Liège, Belgium facilities. - Advancing digital and information strategy including generative AI initiatives.
Guidance
- Raised full year 2026 revenue guidance to $192 million to $196 million. - Believe will achieve positive adjusted EBITDA in the second half of 2026. - Paris, France site already operational with biologistics in November 2025, bioservices to be complemented in Q3 2026; Santa Ana, California site consolidating three existing locations into one with 94,000 square feet, to offer various services including for IntegraCell.
Segment performance
Revenue was $47.8 million, up 16% year over year. Life sciences services segment revenue increased 18% year over year, including 21% growth in bio storage services. Life Sciences product segment generated 15% revenue growth driven by global demand for MVE Biological Solutions cryogenic systems. Revenue in support of commercial cell and gene therapy grew 26% to $9.1 million, while revenue from clinical trials grew 18% to $12.9 million. As of March 31st, supported a record total of 766 global clinical trials, with 91 in Phase 3. Commercial therapies supported increased to 21, with expectation of another ten application filings and up to eight additional new therapy approvals in 2026.
Analyst Q&A
Q: Had 3 million beat vs consensus and raised guide by 2 million, how much prudence and thoughts on 2Q?
A: Think Q2 was outstanding but guide is responsible given global macroeconomic uncertainty, will evaluate quarterly.
Q: MVE Lifescience products had 15% growth, how to think about growth?
A: Products take time to ramp up, markets are solid, expect high single-digit growth.
Q: Seeing biotech funding, any momentum in RFP volumes?
A: Seeing definitive investment into Phase 2 and Phase 3 programs, Phase 3 up five trials sequentially, Phase 2 up almost 30 programs.
Q: Shipped first clinical trial patient material for IntegraCell, initial learnings and expectations?
A: Pleased about supporting clinical processes, IntegraCell is important for long-term revenue and margin expansion, has active projects and additional clients onboarding.
Q: EBITDA side, assumptions to get to 2H positivity?
A: Q1 close to break even on adjusted EBITDA, reaching positive EBITDA in second half driven by revenue growth, new facilities driving profitability.
Q: AI initiatives, durability and savings potential?
A: AI initiatives are durable, focused on enhancing efficiency and effectiveness internally.
Q: Supply chain centers in Paris and Santa Ana, baked into guidance, customer audits and gross margin?
A: Paris site operational with biologistics, bioservices in Q3; Santa Ana site consolidating locations, clients will audit facilities, gross margin expected to start rebounding in second half.
Q: Commercial cell and gene therapy revenue growth rate and breadth?
A: Commercial revenues expected to be strong, 26% growth in Q1 is good, guidance based on existing platform, growth broad-based but can't comment on specific therapies as others haven't reported.
Q: Number of commercial products supported and potential new approvals?
A: Supporting 21 commercial products, potential eight more approvals this year, five have PDUFA dates.
Q: Difference in margins/revenue between commercial and clinical trial products?
A: Commercial therapies driven by patient population and expanding services platform, driving more revenue.
Q: Resurgence in growth, attribution?
A: Broadened revenue stream, bioservices increasing, product demand normalizing.
Q: Commercial acceleration concentration?
A: Cell therapies are majority of commercial customers, gene therapies have even start.
Q: Fusion 800 series pipeline?
A: Early to comment, moving out nicely through distributors.
Q: REMS removal momentum?
A: Community and outpatient hospital growth helps drive revenue.
Q: MVE product margins, energy prices factor?
A: Margin related to product mix, not energy prices.
Q: 2Q activity and sentiment?
A: Overall good for industry, well-funded clients, many phase two and three trials close to finish line.
Q: Pricing structure and inflationary pressures?
A: Fuel surcharges passed on to client base, no impact on product margins from oil prices so far.
Q: Product growth in 2026?
A: Expect high single-digit growth.
Q: IntegraCell volume/size as it ramps?
A: Off to good start, gaining attention, takes time for full ramp but will be important contributor.